GlaxoSmithKline and its Italian research partners are plotting major new European research hubs with future growth in gene therapies and beyond after the CHMP recommended its new "bubble boy" drug for approval in Europe on Friday.
IBM is to establish a beachhead for its European health expansion plans in Italy. The move takes the form of a planned $150 million investment in a Watson Health European Center of Excellence in Milan, which IBM sees acting as the basis of its attempts to grow its healthcare and life science R&D; business in the region.
New analysis published in the Annals of Oncology raises serious questions about the truthfulness and timing involved in the way Clovis Oncology corrected pivotal data on its cancer drug rociletinib.
AstraZeneca, Roche and Sanofi are just three Big Pharma names being touted as possible suitors for the struggling biotech Medivation--but analysts warn it won't come cheap, or easy.
While Coxiella burnetii, the bacterium that causes Q fever, is rarely fatal in humans, it has been aerosolized for use as a biological weapon before. A University of California, Irvine, team won $8 million from the DOD's Defense Threat Reduction Agency to develop a new vaccine against the bacterium.
San Diego-based Zavante Therapeutics has raised $35 million--adding it to an additional $10 million from convertible debt for the Series A round--to back a pivotal study aimed at U.S. approval of an aging antibiotic.
Sanofi Pasteur and the University of Georgia this week talked up details of a next-gen flu vaccine strategy that the pair hopes can build on the strength of current vaccines but broaden protection to avoid the problems associated with strain drift.
Texas is adding more eggs to its incubator as cancer biopharma Tesaro has inked a deal with UT's MD Anderson Cancer Center for new immuno-oncology targets.
The alarm bells are ringing at Alexza Pharmaceuticals as the small biotech announced a weak set of financials and the stark warning that without help, it will likely shut down operations by the summer.
Sanofi has poached Dr. Yong-Jun Liu as its new head of research from MedImmune as it looks to beef up its early-stage pipeline and senior R&D; leadership team.